Reid Hoffman Quits Microsoft Board to Focus on AI Drug Discovery Startup Manus

Reid Hoffman is leaving his long-time role on the Microsoft board to dedicate more time to his latest venture.

The move follows a decade of service that began after the tech giant acquired LinkedIn.

Reid Hoffman's Tech Legacy and Shift

He joined the board in 2016 and helped guide major investments including the early funding of OpenAI.

Hoffman also played a part in other AI deals that shaped the industry landscape.

Now he wants to apply that experience directly as a founder again.

His new focus is Manus, an AI company working on drug discovery for serious diseases like cancer.

AI's Growing Role in Healthcare Breakthroughs

This change highlights a broader trend where experienced leaders return to hands-on startup work in specialized fields.

Manus aims to use advanced AI models to speed up the search for new medicines that could help patients faster than traditional methods.

Such efforts matter because better drug discovery tools may one day lead to more effective treatments reaching people sooner.

Overall the decision shows how top talent is increasingly drawn to practical AI applications that solve real-world problems.

Industry watchers expect more similar moves as AI technology matures in areas like biotechnology.